{"id":980072,"date":"2026-07-09T07:35:58","date_gmt":"2026-07-09T11:35:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-to-present-alzheimers-disease-diagnostic-and-therapeutic-research-at-aaic-2026-including-new-data-on-p-tau217-blood-tests-and-amyloid-targeting-treatment\/"},"modified":"2026-07-09T07:35:58","modified_gmt":"2026-07-09T11:35:58","slug":"lilly-to-present-alzheimers-disease-diagnostic-and-therapeutic-research-at-aaic-2026-including-new-data-on-p-tau217-blood-tests-and-amyloid-targeting-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-to-present-alzheimers-disease-diagnostic-and-therapeutic-research-at-aaic-2026-including-new-data-on-p-tau217-blood-tests-and-amyloid-targeting-treatment\/","title":{"rendered":"Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data<\/i>\n <\/p>\n

\n New data compares the diagnostic performance of P-tau217 blood tests with amyloid positron emission tomography (PET) in cognitively unimpaired Alzheimer’s disease<\/i>\n <\/p>\n

\n Research spanning diagnostics, long-term treatment, disease biology, and patient-centered outcomes reflects Lilly’s 35-year commitment to Alzheimer’s disease science<\/i>\n <\/p>\n

\n INDIANAPOLIS<\/span>, July 9, 2026<\/span> \/PRNewswire\/ —\u00a0Eli Lilly and Company (NYSE: LLY) today announced it will present 16 abstracts at the 2026 Alzheimer’s Association International Conference (AAIC), July 12-15 in London. Three oral presentations anchor the scientific program, with 13 poster presentations spanning imaging science, health economics, real-world prescribing evidence, and patient-centered outcomes, reflecting Lilly’s 35-year commitment to answering open questions in Alzheimer’s disease.<\/p>\n

\n Key Presentations at AAIC 2026<\/b>\n <\/p>\n

\n New Clinical Evidence on Kisunla (donanemab-azbt)<\/i>\n <\/p>\n

On July 15, a Developing Topics Session, Donanemab in Early Symptomatic Alzheimer’s Disease: Evidence to Address Clinical Questions, will present new insights from TRAILBLAZER-ALZ 6 and the TRAILBLAZER-ALZ 2 long-term extension. Findings include new data on safety through modified titration and corticosteroid pretreatment as well as long-term extension evidence on biomarkers and the potential durability of clinical benefit.<\/p>\n

\n Advancing Diagnostics<\/i>\n <\/p>\n

Also on July 15, Samantha Burnham, Ph.D., senior research scientist, Eli Lilly and Company, will present data showing P-tau217 blood biomarker assays demonstrated strong rule-in performance comparable to amyloid PET for identifying Alzheimer’s disease pathology in cognitively unimpaired individuals. Though blood biomarker tests and amyloid PET agents are not currently indicated for use in cognitively unimpaired individuals, the results generate support for a potentially scalable, accessible alternative to specialized imaging in the future.<\/p>\n

\n Advancing Scientific Methodology<\/i>\n <\/p>\n

On July 13, as the organizer of the Featured Research Session, Lars Raket, Ph.D., Eli Lilly and Company, will deliver an oral presentation on external controls versus internal extrapolation in the TRAILBLAZER-ALZ 2 long-term extension (Room N10). The analysis addresses a key methodological question in Alzheimer’s disease research: how long-term outcomes are measured and interpreted in clinical trials, reflecting Lilly’s commitment to the scientific rigor that underpins credible long-term evidence generation.<\/p>\n

A full list of abstracts appears below. Presentations will be available at www.lilly.com<\/a> following their scheduled release times.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n
\n Abstract Title<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Presenter<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Presentation
Type\/#<\/b>
\n <\/span>\n <\/p>\n<\/td>\n

\n

\n
\n Details (Date, Time,
Location, Session Time)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Kisunla (donanemab-azbt)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n External Controls vs. Internal
Extrapolation in the
TRAILBLAZER-ALZ 2 Long-
Term Extension<\/span>\n <\/p>\n<\/td>\n

\n

\n Lars Raket<\/span>\n <\/p>\n<\/td>\n

\n

\n Featured
Research
Session <\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/13\/2026<\/span>\n <\/p>\n

\n Room: N10<\/span>\n <\/p>\n

\n Session: 9-10:30 a.m.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Donanemab in Early
Symptomatic Alzheimer’s
Disease: Evidence to
Address Clinical Questions<\/span>\n <\/p>\n<\/td>\n

\n

\n Nick Fox,<\/span>\n <\/p>\n

\n Emel Serap
Monkul Nery, <\/span>\n <\/p>\n

\n Hong Wang,<\/span>\n <\/p>\n

\n Erin Doty<\/span>\n <\/p>\n<\/td>\n

\n

\n Developing
Topics Session<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/15\/2026 <\/span>\n <\/p>\n

\n 9-10:30 a.m.<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Interim Analysis of the
United Kingdom
Donanemab Controlled
Access Programme: Early
Patient Characteristics and
Prescribing Patterns <\/span>\n <\/p>\n<\/td>\n

\n

\n Krista Schroeder<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/12\/2026<\/span>\n <\/p>\n

\n Poster #8953<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Diagnostics<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Blood Biomarker Assays
Demonstrate Strong Rule-in
Performance for Identifying
Cognitively Unimpaired AD <\/span>\n <\/p>\n<\/td>\n

\n

\n Samantha
Burnham<\/span>\n <\/p>\n<\/td>\n

\n

\n Oral<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/15\/2026<\/span>\n <\/p>\n

\n Room: S11<\/span>\n <\/p>\n

\n Session: 8-8:45 a.m.
\u00a0<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Baseline amyloid and tau
PET characteristics in early
Alzheimer’s Disease: Results
from the TRAILRUNNER-ALZ
3 PET Addendum <\/span>\n <\/p>\n<\/td>\n

\n

\n Ilke Tunali<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/15\/2026<\/span>\n <\/p>\n

\n Biomarkers: Neuroimaging,
8 a.m.- 3 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Evaluation of Diffusion
Tensor Imaging biomarkers
in phase 2 PROSPECT-ALZ
study of Ceperognastat in
early symptomatic
Alzheimer’s disease <\/span>\n <\/p>\n<\/td>\n

\n

\n Ajay Kurani<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/13\/2026
7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Data-Driven Feature Map
Associating Baseline
Florbetapir-PET Uptake
Patterns to ARIA-E Incidence <\/span>\n <\/p>\n<\/td>\n

\n

\n Ian Kennedy<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/13\/2026<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Regional tau PET Extent to
estimate pathological
volume, capture tau
heterogeneity, and detect
treatment response in
clinical trials <\/span>\n <\/p>\n<\/td>\n

\n

\n Vikas Kotari<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/11\/2026 and 7\/14\/2026<\/span>\n <\/p>\n

\n Biomarkers: Neuroimaging,
7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n *Will also be presented at
AIC ahead of AAIC*<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Cross-sectional evaluation of
diffusion tensor imaging
endpoints using three
clinical trials in Alzheimer’s
disease <\/span>\n <\/p>\n<\/td>\n

\n

\n Diana Otero<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/13\/2026<\/span>\n <\/p>\n

\n Biomarkers: Neuroimaging,<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n
\n Health Economics and Outcomes Research (HEOR)<\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Drivers of Increased
Healthcare Utilization and
Medicare Payments During
Cognitively Unimpaired
(Preclinical) Alzheimer’s
Disease Progression<\/span>\n <\/p>\n<\/td>\n

\n

\n Zachary Sheff<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/12\/2026 <\/span>\n <\/p>\n

\n Poster #441<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Neurocognitive, Biomarker,
and Health Outcomes in
Those at Risk for Alzheimer’s
Disease Symptoms:
ANCHOR-AD Study Design<\/span>\n <\/p>\n<\/td>\n

\n

\n Nalin Payakachat<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/14\/2026<\/span>\n <\/p>\n

\n Poster #9036<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Incident institutionalization
rates among Medicare
beneficiaries with
Alzheimer’s disease or mild
cognitive impairment<\/span>\n <\/p>\n<\/td>\n

\n

\n Zachary Sheff<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/12\/2026<\/span>\n <\/p>\n

\n Poster # 7262<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Risk Algorithms to Predict
Elevated Plasma P-tau217
Status: A Cross-sectional
Analysis <\/span>\n <\/p>\n<\/td>\n

\n

\n Nalin Payakachat<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/12\/2026<\/span>\n <\/p>\n

\n Poster # 2141<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n

\n Natural Language Processing
(NLP) Algorithms to Identify
Intracerebral Hemorrhage
>1 cm and Amyloid-Related
Imaging Abnormalities
(ARIA) in US Electronic
Medical Records<\/span>\n <\/p>\n<\/td>\n

\n

\n Krista Schroeder<\/span>\n <\/p>\n<\/td>\n

\n

\n Poster<\/span>\n <\/p>\n<\/td>\n

\n

\n 7\/15\/2026<\/span>\n <\/p>\n

\n Poster # 8947<\/span>\n <\/p>\n

\n 7:30 a.m.-4:15 p.m.<\/span>\n <\/p>\n

\n Exhibit Hall<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

\n About Alzheimer’s Disease
<\/b>By 2030, an estimated 78 million people worldwide are projected to have Alzheimer’s disease, rising from approximately 55 million today, from those living with the earliest changes associated with the disease, to those experiencing profound memory loss.\u00b9 The disease begins silently, often decades before any change in memory or thinking, with the accumulation of amyloid plaques in the brain,2<\/sup> progressing through stages of increasing memory loss, behavioral changes, and growing dependence on caregivers.3
<\/sup><\/p>\n

Nearly 4 in 5 Americans say they would want to know if they had Alzheimer’s disease before experiencing symptoms or before symptoms interfere with their daily activities.4<\/sup> \u00a0<\/p>\n

\n About<\/b>\u00a0Kisunla\u00ae<\/sup> (donanemab-azbt)
<\/b>Kisunla is currently approved as an amyloid-targeting treatment for people with mild cognitive impairment as well as people with mild dementia stage of early symptomatic Alzheimer’s disease with confirmed amyloid pathology. Kisunla is a humanized monoclonal antibody that targets and reduces insoluble N-truncated pyroglutamate amyloid beta plaques, a defining feature of Alzheimer’s disease, and is administered as an intravenous infusion every four weeks. Kisunla can cause serious side effects, including ARIA and infusion-related reactions. Apolipoprotein E \u03b54 (ApoE \u03b54) homozygotes have a higher incidence of ARIA, including symptomatic and serious ARIA, and testing for ApoE \u03b54 status should be performed prior to initiating treatment. Carriers of one or two copies of the ApoE \u03b54 gene may be at higher risk of developing Alzheimer’s disease and experiencing ARIA. Patients should discuss any safety concerns with their healthcare providers.<\/p>\n

\n INDICATION AND SAFETY SUMMARY WITH WARNINGS<\/b>
\n
\n Kisunla\u00ae<\/sup><\/b>\u00a0(kih-SUHN-lah) <\/b>is used to treat adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or mild dementia stage of disease. \u00a0<\/p>\n

\n Warnings –<\/b>\u00a0Kisunla<\/b>\u00a0can cause Amyloid-Related Imaging Abnormalities or “ARIA.” This is a common side effect that does not usually cause any symptoms, but serious symptoms can occur. ARIA can be fatal.<\/b>\u00a0ARIA is\u00a0most commonly seen\u00a0as\u00a0temporary swelling in an area or areas of the brain that usually goes away over time. Some people may also have spots of bleeding on the surface of or in the\u00a0brain\u00a0and infrequently, larger areas of bleeding in the brain can occur. Although most people do not have symptoms, some people have: \u00a0<\/p>\n

\n\n\n
\n

\n <\/span>\n <\/p>\n

    \n
  • \n Headache<\/span>\n <\/li>\n
  • \n Dizziness<\/span>
    \n \u00a0<\/span>
    \n \u00a0<\/span>\n <\/li>\n
  • \n Nausea<\/span>
    \n \u00a0<\/span>\n <\/li>\n
  • \n Difficulty
    walking<\/span>\n <\/li>\n<\/ul>\n<\/td>\n
\n

\n <\/span>\n <\/p>\n